Charles Loprinzi, MD, Giant of Cancer Care: Supportive/Palliative Care, Mayo Clinic, discusses potential treatments for chemotherapy-induced peripheral neuropathy (CIPN).

Duloxetine has demonstrated benefits in managing CIPN in clinical trials, but Loprinzi adds that the benefits are not great and the drug is associated with some toxicities.Â 

Loprinzi says minocycline, which is commonly used to treat acne, has promising preclinical data in preventing neuropathy. Pilot studies for the drug are ongoing.Â 

Another method being tested for the treatment of CIPN is Scrambler therapy, in which electrodes are placed on the skin in areas around sites of pain. Electrical signals send non-pain messages to areas that are interpreting chronic pain, such as that caused by neuropathy. This therapy has not been proven effective in treating CIPN, but Loprinzi says that he is convinced it can help a number of patients in this population.Â 

Articles

Charles Loprinzi, MD, Giant of Cancer Care: Supportive/Palliative Care, Mayo Clinic, discusses potential treatments for chemotherapy-induced peripheral neuropathy (CIPN).


Charles Loprinzi on Potential Treatments for Chemotherapy-Induced Peripheral Neuropathy

Charles Loprinzi, MD, Mayo Clinic, discusses managing chemotherapy-induced peripheral neuropathy in adult patients with cancer. 

When patients present with symptoms of chemotherapy-induced neuropathy, healthcare professionals need to weigh the benefits of continuing therapy. 

Loprinzi says that he tends to stop treatment early in patients with neuropathy in order to prevent the condition from becoming chronic. 

Charles Loprinzi, MD

Articles

Charles Loprinzi on Potential Treatments for Chemotherapy-Induced Peripheral Neuropathy

Charles Loprinzi on Chemotherapy-Induced Peripheral Neuropathy